{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:04:13Z","timestamp":1777363453838,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05847-0","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T02:01:30Z","timestamp":1719021690000},"page":"3605-3613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study"],"prefix":"10.1007","volume":"103","author":[{"given":"Leyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"5","key":"5847_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Primary myelofibrosis (2023) 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(5):801\u2013821. https:\/\/doi.org\/10.1002\/ajh.26857","journal-title":"Am J Hematol"},{"issue":"17","key":"5847_CR2","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F (2014) How I treat myelofibrosis. Blood 124(17):2635\u20132642. https:\/\/doi.org\/10.1182\/blood-2014-07-575373","journal-title":"Blood"},{"key":"5847_CR3","doi-asserted-by":"publisher","unstructured":"Tefferi A, Lasho TL, Jimma T et al (2012) One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. ;87(1):25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","DOI":"10.1016\/j.mayocp.2011.11.001"},{"issue":"5","key":"5847_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL et al (2018) Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32(5):1254\u20131258. https:\/\/doi.org\/10.1038\/s41375-018-0028-x","journal-title":"Leukemia"},{"issue":"9","key":"5847_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"5847_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"1","key":"5847_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","volume":"9","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Odenike O, Singer JW et al (2016) Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 9(1):137. https:\/\/doi.org\/10.1186\/s13045-016-0367-x","journal-title":"J Hematol Oncol"},{"key":"5847_CR8","unstructured":"Incyte Jakafi (ruxolitinib) (2021) prescribing information https:\/\/www.jakafi.com\/pdf\/prescribing-information. pdf Accessed 5th May 2023"},{"issue":"4","key":"5847_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM et al (2014) Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20(4):408\u2013414. https:\/\/doi.org\/10.1038\/nm.3512","journal-title":"Nat Med"},{"issue":"8","key":"5847_CR10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","volume":"133","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U (2019) Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 133(8):790\u2013794. https:\/\/doi.org\/10.1182\/blood-2018-11-876888","journal-title":"Blood"},{"issue":"1","key":"5847_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-019-01251-5","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A, Luspatercept (2020) First Approval Drugs 80(1):85\u201390. https:\/\/doi.org\/10.1007\/s40265-019-01251-5","journal-title":"First Approval Drugs"},{"issue":"2","key":"5847_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ et al (2020) Luspatercept in patients with Lower-Risk Myelodysplastic syndromes. N Engl J Med 382(2):140\u2013151. https:\/\/doi.org\/10.1056\/NEJMoa1908892","journal-title":"N Engl J Med"},{"key":"5847_CR13","doi-asserted-by":"publisher","first-page":"106430","DOI":"10.1016\/j.leukres.2020.106430","volume":"97","author":"J Feld","year":"2020","unstructured":"Feld J, Navada SC, Silverman LR (2020) Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia. Leuk Res 97:106430. https:\/\/doi.org\/10.1016\/j.leukres.2020.106430","journal-title":"Leuk Res"},{"issue":"5","key":"5847_CR14","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41375-022-01521-4","volume":"36","author":"RS Komrokji","year":"2022","unstructured":"Komrokji RS, Platzbecker U, Fenaux P et al (2022) Luspatercept for myelodysplastic syndromes\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia 36(5):1432\u20131435. https:\/\/doi.org\/10.1038\/s41375-022-01521-4","journal-title":"Leukemia"},{"issue":"20","key":"5847_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"2","key":"5847_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437\u2013438. https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"issue":"9","key":"5847_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"8","key":"5847_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R et al (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20131398. https:\/\/doi.org\/10.1182\/blood-2013-03-488098","journal-title":"Blood"},{"issue":"Supplement1","key":"5847_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Vannucchi AM, Passamonti F et al (2019) A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Blood 134(Supplement1):557\u2013557","journal-title":"Blood"},{"key":"5847_CR20","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1200\/JCO.2023.41.16_suppl.7016","volume":"41","author":"AT Gerds","year":"2023","unstructured":"Gerds AT, Harrison C, Kiladjian J-J et al (2023) Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: results from the ACE-536-MF-001 study. JCO 41:7016\u20137016. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7016","journal-title":"JCO"},{"issue":"Suppl 1","key":"5847_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-137265","volume":"136","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, Vannucchi AM, Passamonti F et al (2020) Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF)\u2013updated data from the phase 2 ACE-536-MF-001 study. Blood 136(Suppl 1):47\u201348","journal-title":"Blood"},{"issue":"1","key":"5847_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000521889","volume":"15","author":"NK Yun","year":"2022","unstructured":"Yun NK, Alrifai T, Miller IJ et al (2022) Transfusion independence achieved with combination fedratinib and Luspatercept in an Elderly Man with heavily pretreated Intermediate-2 risk primary myelofibrosis. Case Rep Oncol 15(1):126\u2013132. https:\/\/doi.org\/10.1159\/000521889","journal-title":"Case Rep Oncol"},{"issue":"12","key":"5847_CR23","doi-asserted-by":"publisher","first-page":"E474","DOI":"10.1002\/ajh.26749","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, Chetram D, McCullough K et al (2022) Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts. Am J Hematol 97(12):E474\u2013E477. https:\/\/doi.org\/10.1002\/ajh.26749","journal-title":"Am J Hematol"},{"issue":"10","key":"5847_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, G\u00f6tze KS et al (2017) Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol 18(10):1338\u20131347. https:\/\/doi.org\/10.1016\/S1470-2045(17)30615-0","journal-title":"Lancet Oncol"},{"issue":"8","key":"5847_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.6004\/jnccn.2022.7040","volume":"20","author":"V Mehta","year":"2022","unstructured":"Mehta V, Sheni R (2022) Time for timeliness: a proposal for establishing time to treatment initiation as a quality measure. J Natl Compr Canc Netw 20(8):854\u2013856. https:\/\/doi.org\/10.6004\/jnccn.2022.7040","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"5847_CR26","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/ehf2.13646","volume":"8","author":"A Abdin","year":"2021","unstructured":"Abdin A, Anker SD, Butler J et al (2021) Time is prognosis\u2019 in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail 8(6):4444\u20134453. https:\/\/doi.org\/10.1002\/ehf2.13646","journal-title":"ESC Heart Fail"},{"issue":"7","key":"5847_CR27","doi-asserted-by":"publisher","first-page":"8166","DOI":"10.1002\/cam4.5618","volume":"12","author":"G Coltro","year":"2023","unstructured":"Coltro G, Sant\u2019Antonio E, Palumbo GA et al (2023) Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: an Italian MYNERVA Project. Cancer Med 12(7):8166\u20138171. https:\/\/doi.org\/10.1002\/cam4.5618","journal-title":"Cancer Med"},{"key":"5847_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.leukres.2017.07.008","volume":"60","author":"CR Cogle","year":"2017","unstructured":"Cogle CR, Reddy SR, Chang E et al (2017) Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leuk Res 60:123\u2013128. https:\/\/doi.org\/10.1016\/j.leukres.2017.07.008","journal-title":"Leuk Res"},{"issue":"2","key":"5847_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","volume":"111","author":"S Park","year":"2008","unstructured":"Park S, Grabar S, Kelaidi C et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111(2):574\u2013582. https:\/\/doi.org\/10.1182\/blood-2007-06-096370","journal-title":"Blood"},{"issue":"33","key":"5847_CR30","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.21.02476","volume":"40","author":"U Platzbecker","year":"2022","unstructured":"Platzbecker U, G\u00f6tze KS, Kiewe P et al (2022) Long-term efficacy and safety of Luspatercept for Anemia treatment in patients with Lower-Risk Myelodysplastic syndromes: the phase II PACE-MDS study. J Clin Oncol 40(33):3800\u20133807. https:\/\/doi.org\/10.1200\/JCO.21.02476","journal-title":"J Clin Oncol"},{"key":"5847_CR31","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ, Momelotinib (2023) First Approval Drugs 83:1709\u20131715. https:\/\/doi.org\/10.1007\/s40265-023-01964-8","journal-title":"First Approval Drugs"},{"issue":"18","key":"5847_CR32","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"ST Oh","year":"2020","unstructured":"Oh ST, Talpaz M, Gerds AT et al (2020) ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 4(18):4282\u20134291. https:\/\/doi.org\/10.1182\/bloodadvances.2020002662","journal-title":"Blood Adv"},{"issue":"34","key":"5847_CR33","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV et al (2017) SIMPLIFY-1: a phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus kinase Inhibitor\u2013Na\u00efve patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418","journal-title":"J Clin Oncol"},{"issue":"10373","key":"5847_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM et al (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0","journal-title":"Lancet"},{"key":"5847_CR35","doi-asserted-by":"publisher","unstructured":"Malte Asshoff V, Petzer, Matthew R (2017) el at. Andrew Whitney, Igor Theurl; Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood ; 129 (13): 1823\u20131830. https:\/\/doi.org\/10.1182\/blood-2016-09-740092","DOI":"10.1182\/blood-2016-09-740092"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05847-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:13:39Z","timestamp":1724836419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5847"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05847-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with guidelines of the ethics committee of Peking Union Medical College Hospital and the revised Helsinki Declaration of 2008 (5).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was provided by all patients who took part in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no potential conficts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}